CA68405H1001
© Newsfile
26.11.2025
OPTI
LISTED
CSE
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
News Preview
Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSDVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of phar...
Themefolio
Profiler
Peergroup
© Newsfile
21.10.2025
OPTI
LISTED
CSE
Optimi Health Provides Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspect...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2025
OPTI
LISTED
CSE
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
News Preview
Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSDVancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GM...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
08.09.2025
OPTI
LISTED
CSE
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") rel...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
03.09.2025
OPTI
LISTED
CSE
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
News Preview
Export of 1,000 natural psilocybin capsules for prescription use under Australia's Authorised Prescriber Scheme follows the Company's successful launch of MDMA sales in 2024Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacture...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
OPTI
LISTED
CSE
Optimi Health Provides Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi wi...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2025
OPTI
LISTED
CSE
Early Warning Press Release in Accordance with National Instrument 62-103
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 25, 2025) - Catcher Investments Ltd. (the "Acquiror") acquired 3,000 unsecured convertible debentures (each a "Convertible Debenture") of Optimi Health Corp. (the "Issuer") at a price of CAD$1,000 per Convertible Debenture for a total investment of CAD$3,000,000 pursuant to a non-brokered private...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2025
OPTI
LISTED
CSE
Early Warning Press Release in Accordance with National Instrument 62-103
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 25, 2025) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 450 unsecured convertible debentures (each a "Convertible Debenture") of Optimi Health Corp. (the "Issuer") at a price of CAD$1,000 per Convertible Debenture for a total investment of CAD$450,000 pursuant to a non-brokered priva...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2025
OPTI
LISTED
CSE
Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2025
OPTI
LISTED
CSE
Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
News Preview
1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veteransVancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2025
OPTI
LISTED
CSE
Optimi Health Obtains U.S. FDA Drug Establishment Registration
News Preview
The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States.Vancouver, British Columbia--(Newsfile Corp. - May 5, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocyb...
Themefolio
Profiler
Peergroup
© Newsfile
12.03.2025
OPTI
LISTED
CSE
Optimi Health Provides Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA, is pleased to provide the following corporate update, highlighting key regulatory milestones, clin...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
29.01.2025
OPTI
LISTED
CSE
Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
News Preview
Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and CanadaVancouver, British Columbia--(Newsfile Corp. - January 29, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, GMP-grade psilocybin and M...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2025
OPTI
LISTED
CSE
Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it has closed the second and final tranche (the "Second Tra...
Themefolio
Profiler
Peergroup
© Newsfile
17.01.2025
OPTI
LISTED
CSE
Optimi Health Provides Corporate Update
News Preview
Non-Brokered Private Placement and Debt SettlementVancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intend...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2025
OPTI
LISTED
CSE
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
News Preview
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks.Vancouver, British Columbia--(Newsfile Corp. - January 13, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psyche...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2025
OPTI
LISTED
CSE
Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is pleased to announce the completion of its second shipment of GMP-certified MDMA...
Themefolio
Profiler
Peergroup
© Newsfile
17.12.2024
OPTI
LISTED
CSE
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
News Preview
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP-certified,...
Themefolio
Profiler
Peergroup
© Newsfile
23.10.2024
OPTI
LISTED
CSE
Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
News Preview
Additional 700 Doses Ordered by Mind Medicine Australia as Demand SurgesVancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud...
Themefolio
Profiler
Peergroup
© Newsfile
21.10.2024
OPTI
LISTED
CSE
Optimi Health Announces Leadership Transition
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief E...
Themefolio
Profiler
Peergroup
© Newsfile
28.08.2024
OPTI
LISTED
CSE
Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
News Preview
Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapyVancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceutica...
Themefolio
Profiler
Peergroup
© Newsfile
16.08.2024
OPTI
LISTED
CSE
Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's G...
Themefolio
Profiler
Peergroup
© Newsfile
13.08.2024
OPTI
LISTED
CSE
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
News Preview
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence"), a develop...
Themefolio
Profiler
Peergroup
© Newsfile
07.08.2024
OPTI
LISTED
CSE
Optimi Health Announces Non-Brokered Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up...
Themefolio
Profiler
Peergroup
© Newsfile
23.07.2024
OPTI
LISTED
CSE
Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
News Preview
Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authoritiesVancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedeli...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2024
OPTI
LISTED
CSE
Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the launch of OptiMed, an onli...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
OPTI
LISTED
CSE
Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia's Authorised Prescriber Scheme
News Preview
The Company will ship 160 doses of MDMA and psilocybin to Australian psychiatrists for the treatment of patients with PTSD and Treatment-Resistant Depression.Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant p...
Themefolio
Profiler
Peergroup
© Newsfile
11.06.2024
OPTI
LISTED
CSE
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce a series of mileston...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
